INSTITUT CLAUDIUS REGAUD

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.claudiusregaud.fr

Clinical Trials

Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.

Phase 2

Completed

Conditions: Localized Prostate Cancer

Interventions: Radiation: Focal brachytherapy

First Posted Date: 2013-07-18

Last Posted Date: 2018-08-06

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 18

Registration Number: NCT01902680

Locations: 🇫🇷
Institut Claudius REGAUD, Toulouse, France

Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study

Not Applicable

Completed

Conditions: Glioblastoma

Interventions: Procedure: Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol

First Posted Date: 2013-06-07

Last Posted Date: 2018-08-27

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 21

Registration Number: NCT01872221

Locations: 🇫🇷
Institut Claudius REGAUD, Toulouse, France
🇫🇷
CHU Rangueil, Toulouse, France

Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions Synchronized With Breath for the Assessment of Extension of Lung Cancer

Not Applicable

Terminated

Conditions: Lung Nodule
Non Small Cell Lung Cancer

Interventions: Device: PET/CT 4D imaging in a synchronized mode centered on the thorax.

First Posted Date: 2012-11-02

Last Posted Date: 2014-10-09

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 46

Registration Number: NCT01720186

Locations: 🇫🇷
Institut Claudius REGAUD, Toulouse, France

Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria

Phase 1

Terminated

Conditions: Metastatic Cancer (Different Solid Tumour Types)

Interventions: Drug: Pazopanib

First Posted Date: 2012-07-17

Last Posted Date: 2018-08-06

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 18

Registration Number: NCT01642017

Locations: 🇫🇷
Hôpital Saint André, Bordeaux, France
🇫🇷
Centre François BACLESSE, Caen, France
🇫🇷
Institut Claudius REGAUD, Toulouse, France

and more 1 locations

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Tamoxifen, Letrozole , Anastrozole, Exemestane

First Posted Date: 2012-06-06

Last Posted Date: 2018-03-05

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 39

Registration Number: NCT01612871

Locations: 🇫🇷
Institut Claudius REGAUD Toulouse, Toulouse, France
🇫🇷
Centre Val d'Aurelle - Paul Lamarque, Montpellier, France

Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival

Phase 4

Completed

Conditions: Metastatic Breast Cancer Starting a Third Line Chemotherapy

First Posted Date: 2012-04-10

Last Posted Date: 2023-06-13

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 267

Registration Number: NCT01574170

Locations: 🇫🇷
Institut de Cancérologie de l'Ouest Paul Papin, Angers, France
🇫🇷
C.M.C.O. Claude Bernard, Albi, France
🇫🇷
CHU Jean Minjoz, Besançon, France

and more 13 locations

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Tamoxifen,
Drug: Exemestane
Drug: Anastrozole
Drug: Letrozole

First Posted Date: 2012-03-14

Last Posted Date: 2013-06-04

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 29

Registration Number: NCT01553903

Locations: 🇫🇷
Institut Claudius REGAUD, Toulouse, France

Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma

Phase 3

Terminated

Conditions: Glioblastoma

Interventions: Radiation: Radiotherapy
Radiation: Experimental arm

First Posted Date: 2012-01-11

Last Posted Date: 2021-01-12

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 180

Registration Number: NCT01507506

Locations: 🇫🇷
Centre Paul Strauss, Strasbourg, France
🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Clinique Claude Bernard, Albi, France

and more 9 locations

Pharmacology of Adjuvant Hormonotherapy in Breast Cancer

Phase 4

Completed

Conditions: Hormono-depending Adjuvant Breast Cancer

Interventions: Drug: Tamoxifen, Letrozole, Anastrozole or Exemestane

First Posted Date: 2010-05-20

Last Posted Date: 2018-03-02

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 2000

Registration Number: NCT01127295

Locations: 🇫🇷
CHU de Bordeaux, Bordeaux, France
🇫🇷
Centre Hospitalier d'Auch, Auch, France
🇫🇷
Clinique Claude Bernard, Albi, France

and more 21 locations

Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

Phase 1

Completed

Conditions: Locally Advanced Non Small Cell Lung Cancer (NSCLC)

Interventions: Drug: cilengitide, radiochemotherapy

First Posted Date: 2010-05-07

Last Posted Date: 2022-05-24

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 14

Registration Number: NCT01118676

Locations: 🇫🇷
CHU Toulouse Larrey, Toulouse, France
🇫🇷
Institut Claudius Regaud, Toulouse, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy